The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 17, 2026 at 2:30 PM instead of 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 17, 2026 at 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

Alpha Credit Rating PLC. has assigned Surveillance rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook based on audited financial statement for the year ended 30 June of FY 2024-2025, unaudited financial statement for the 3rd quarter ended March 2026 and relevant qualitative information till 14 September, 2026.

The company has informed that it has expanded its presence in the European market by dispatching its first consignment of therapeutics to Portugal. The initial launch includes Amantadine 100 mg capsules, manufactured at EU-GMP-approved Rajendrapur General Facility, alongside Fludrocortisone 0.1 mg tablets & Cabergoline 0.5 mg tablets, produced at EU-GMP-approved Mirpur Potent Facility. This entry into Portugal represents a significant step in Renata's ongoing international expansion strategy across Europe.

The company has informed that it has received approval for its Levothyroxine Sodium tablets under the EU Decentralised Procedure (DCP) in Ireland, Germany, Italy, Poland, Portugal and Malta. The product will be manufactured at Renata's EU GMP-approved potent product facility. Renata PLC intends to support safe and reliable access to Levothyroxine in the newly approved EU markets.

(Q3 Un-audited): Consolidated EPS was Tk. 6.81 for January-March 2026 as against Tk. 5.12 for January-March 2025; Consolidated EPS was Tk. 20.39 for July 2025-March 2026 as against Tk. 15.95 for July 2024-March 2025. Consolidated NOCFPS was Tk. 22.40 for July 2025-March 2026 as against Tk. 21.76 for July 2024-March 2025. Consolidated NAV per share was Tk. 320.02 as on March 31, 2026, and Tk. 305.49 as on June 30, 2025.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 2:30 PM to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

(Cont. News of RENATA): NOCFPS: The improvement was primarily attributable to strong growth in operating profit. Enhanced working capital management, reflected in lower cash tied up with inventories and trade and other receivables compared to the six-month period ended 31 December 2024, also contributed to the increase. In addition, higher depreciation and amortisation, as non-cash adjustments to profit before tax, further supported the growth in NOCF. (end)

The company has informed that it has received Marketing Authorization (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom, for Esomeprazole 20 mg and 40 mg Gastro-Resistant Tablets. This approval allows the product to be marketed in the UK, a highly regulated pharmaceutical market.

The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.